DelveInsight's 'Systemic Lupus Erythematosus Pipeline Insight 2024' report provides comprehensive global coverage of pipeline systemic lupus erythematosus therapies in various stages of clinical ...
After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...
Zacks.com on MSN6h
FATE Presents Encourgaing Data From Lupus Study, Stock GainsFate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in ...
The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...
Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...
In a new study, researchers discovered a potential new gene biomarker, ELF1, a protein coding gene, that can be used to ...
Natural treatments for lupus are typically used as complementary therapies alongside conventional treatments. Learn more ...
Fate said it is also enrolling a second treatment arm under the Phase 1 Autoimmunity study to evaluate a single dose of FT819 ...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...
The 1.5 million Americans estimated to have the autoimmune disease lupus already have plenty to manage—what with the pain, ...
Leerink Partners analyst Andrew Berens reiterated a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback